Silicon Investor - NNVC - NanoViricides, Inc.

[Savant] another claim.... NanoViricides Files for Orphan Drug Status as U.S. Measles C...

Savant — 2/12/2026 12:35:24 PM

another claim.... NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX)
Posted on February 12, 2026

NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX) | ABNewswire

**yet another claim...time will tell

[Savant] HtF... I'm waiting for the lifetime longevity cure...I'm sure it's coming...lol

Savant — 11/17/2025 6:03:36 PM

[HardToFind] I'm waiting for the mRNA version of NV-387. Take it once and NV-387 is in your s...

HardToFind — 11/17/2025 4:06:05 PM

I'm waiting for the mRNA version of NV-387. Take it once and NV-387 is in your system for life. No more viruses for you!!!

[Savant] Another claim by a company that can 'cure anything'... NNVC - BioMedNewsBre...

Savant — 7/21/2025 11:38:47 AM

Another claim by a company that can 'cure anything'... NNVC - BioMedNewsBreaks - NanoViricides (NYSE American: NNVC) Reports Breakthrough Measles Drug Success in Humanized Animal Study

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage developer of broad-spectrum antivirals using host-mimetic nanomedicine, announced promising results for NV-387, its lead drug candidate, in treating Measles. In a lethal respiratory infection model using humanized mice, NV-387 increased survival by 130%—from 7.4 to 17 days—with no observed toxicity and dose-dependent efficacy. The drug mimics human cell features to bind and neutralize viruses, targeting over 90% of human pathogens. With global Measles cases surging and vaccine coverage declining, the Company emphasized the urgent need for a therapeutic option. “NV-387 is on its way to become the very first drug to treat Measles,” said Anil R. Diwan, PhD.

NNVC - BioMedNewsBreaks - NanoViricides (NYSE American:...

[Savant] Another claim to be able to FiX a new variant... vaporware? NNVC - With R...

Savant — 6/18/2025 10:32:25 AM

Another claim to be able to FiX a new variant... vaporware? NNVC - With Rising Variants of COVID and Bird Flu the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness Says NanoViricides' Dr. Diwan

Nimbus, a new COVID variant, officially NB1.8.1, is displacing the LP8.1 variant that was dominant until a few weeks ago in the USA (https://pr.report/bn4n).

Nimbus has been rising globally since Spring according to WHO (https://pr.report/bn4o).

Nimbus causes "razor-sharp" sore throat in some individuals, which is extremely painful and lingering for some time, in addition to the usual COVID symptoms.

Nimbus is more resistant to antibodies generated from previous vaccines, although prior vaccination or natural COVID infection is expected to still be protective in terms reduced severity compared to without such immunity according to CDC.

NNVC - With Rising Variants of COVID and Bird Flu the...

[Savant] Never misses a chance to claim to be able to 'fix' something>>>> Claim they're ...

Savant — 4/14/2025 10:59:04 AM

Never misses a chance to claim to be able to 'fix' something>>>> Claim they're the answer to measles outbreak ....... Security Check

Lots of claims over the years...but so far...nada

[HardToFind] Safe assumption. I was a fan, but not in the last few years. My lessons: 1. Nev...

HardToFind — 1/22/2025 11:36:16 AM

Safe assumption. I was a fan, but not in the last few years.

My lessons:
1. Never invest in a company where the CEO has a side deal (Theracour) that allows himself to profit when the shareholders do not (a.k.a. "double dealing")
2. Give up when the company cannot deliver a drug after 20 years of successful pre-clinical data.

[starting_out] Assuming you're not a fan?

starting_out — 1/22/2025 10:50:12 AM

[HardToFind] Happy New Year 2025!!! I hope we all have learned a few lessons from this stock...

HardToFind — 1/5/2025 2:20:08 AM

Happy New Year 2025!!!

I hope we all have learned a few lessons from this stock that we can apply to our future investments and speculations!

[Savant] big difference>>> NV-387 Can Advance Directly into Phase II Human Clinical Tri...

Savant — 7/11/2023 3:43:46 PM

big difference>>>
NV-387 Can Advance Directly into Phase II Human Clinical Trials

VERSUS

It is expected that NV-387 can be advanced into Phase II studies

PS, Pump faded fast

[drkaz] Interesting news today and nice effect on the share price. Company’s Broad-Spe...

drkaz — 7/11/2023 10:46:29 AM

Interesting news today and nice effect on the share price.

Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
finance.yahoo.com

SHELTON, CT / ACCESSWIRE / July 11, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV (Respiratory Syncytial Virus).

NV-387 Can Advance Directly into Phase II Human Clinical Trials for RSV Treatment:
NV-387 is the active ingredient of NV-CoV-2, the Company's drug for the treatment of COVID and possibly long COVID. It is already in Phase 1a/1b human clinical trials for the evaluation of safety in healthy volunteers and of safety and preliminary efficacy in COVID patients as previously reported.

It is expected that NV-387 can be advanced into Phase II studies against RSV once the current Phase I studies of NV-CoV-2 are completed. This will significantly speed up the development of the RSV drug, save costs, and improve return on investments (ROI).

"We are very pleased with the extremely high effectiveness of NV-387 in combating RSV", said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "Importantly, both oral administration and intravenous injection of NV-387 were highly effective. This study further establishes the broad-spectrum antiviral effectiveness of NV-387, and further solidifies our novel nanoviricides platform technology."

RSV is an Important Acute Lower Respiratory Infection (ALRI; includes Pneumonia)[1]:
Each year in the United States, an estimated 58,000-80,000 children younger than 5 years old are hospitalized due to RSV infection. Globally, RSV is a common cause of childhood ALRI and a major cause of hospital admissions in young children. Globally in 2015, 33 million episodes of RSV-ALRI, resulted in about 3·2 million hospital admissions, and 59,600 in-hospital deaths in children younger than 5 years. About 45% of hospital admissions and in-hospital deaths due to RSV-ALRI occur in children younger than 6 months.

There are No Effective Treatments for RSV:
Two vaccines have recently been approved for RSV prophylaxis. Arexvy (GSK), and Abrysvo (Pfizer) were approved in May, 2023 for use in adults over 60 years of age and both reduced severity of RSV infection. There are no vaccines currently approved for infants and children.

However, there are no effective therapeutics for RSV to date. Ribavirin is conditionally approved only for patients with high risk of progressively severe RSV disease, due to significant side effects including hemolytic anemia and kidney failure. Synagis (palivizumab), an antibody, is approved only as a prophylactic in children and infants at high risk of severe RSV infection, but it is not approved for treatment of RSV infection.

Market Size of RSV Therapeutics is Expected to Hit US$ 8.73 Billion by 2031[2]:
GrowthPlus Reports, in June 2023, says the market size for RSV therapeutics was worth $1.8 Billion in 2022, and is expected to grow at a CAGR of 18.9%, reaching $8.73 Billion by 2031.

NV-387 Injection was Found to be Highly Effective Against a Lethal Direct-Lung RSV infection in a Mouse Model:
Animals treated with injection vehicle solution alone survived 7 days. Ribavirin, a toxic drug, was used as a positive control. Animals treated with injections of ribavirin survived 16 days, whereas animals treated with injectable NV-387 survived 15 days, almost matching the efficacy of ribavirin treatment.

NV-387 Administered by Oral Gavage was also Found to be Highly Effective in the Same Lethal Direct-Lung RSV Infection Study:
Animals treated with oral drug vehicle alone survived 7 days. Orally administered Ribavirin, a toxic drug, was used only as a positive control. Animals treated with oral ribavirin survived 16 days, whereas animals treated with oral NV-387 survived 15 days, again almost matching the efficacy of ribavirin treatment.

Unlike ribavirin, NV-387 has been found to be extremely safe in preclinical studies. Therefore, it would be possible to increase the dose level or frequency of NV-387 to increase its effectiveness. Thus this study demonstrates that NV-387 is a highly effective drug candidate for the treatment of RSV infection with significant patient benefits.

NV-387 Demonstrated Very High Oral Bioavailability in This Study:
The dosing of NV-387 orally given was twice as much as that given by I.V. injection to compensate for oral bioavailability. The apparent oral bioavailability of NV-387 based on efficacy parameters appears to be of the order of almost 50% in this study, a very high value.

NV-387 Acts by a Novel Mechanism:
The Company developed NV-387 in response to the COVID pandemic as a broad-spectrum, pan-coronavirus antiviral. It was designed to "look like a cell" to the virus, displaying copious amounts of sites to which the virus binds on the surface of the nanoviricide nanomicelle, to trap and destroy the virus particle, rendering it incapable of infecting another cell.

The Company calls this novel antiviral mechanism "Re-Infection Blocker".

Expanding Indications of NV-387:
NV-387 employs mimics of well known attachment sites on the cells commonly used by viruses called sulfated proteoglycans. Since these attachment receptors are used by over 90% of human pathogenic viruses, the Company anticipated that NV-387 may have effectiveness against many viruses beyond coronaviruses, our initial focus.

RSV is the first non-coronavirus that the Company has evaluated for susceptibility to NV-387.

About NanoViricides

NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-CoV-2 for the treatment of COVID caused by SARS-CoV-2 coronavirus. Our other advanced candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project exact dates for the regulatory activities in progressing its drug candidates because of the Company's significant dependence on external collaborators and consultants. The Company is currently focused on advancing NV-CoV-2 through Phase I/II human clinical trials.

NV-CoV-2 is the Company's nanoviricide drug candidate for COVID. NV-CoV-2-R is another drug candidate for COVID that is made up of NV-CoV-2 with Remdesivir, an already approved drug, encapsulated within its polymeric micelles. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing a broad pipeline of drugs against a number of viruses, with preclinical safety and effectiveness successes achieved already in many cases. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses, enteroviruses, and other viruses that it engages into research for, if the initial research is successful. TheraCour has not denied any licenses requested by the Company to date. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Disclosure Statement: This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and that could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. In particular, as is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety in human clinical trials to lead to a successful pharmaceutical product, including our coronavirus drug development program.

[1] Lancet 2017; 390: 946-58

[2] finance.yahoo.com .

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
MJ Clyburn
TraDigital IR
clyburn@tradigitalir.com

SOURCE: NanoViricides, Inc.

[old 'n cranky] FWIW they had an open s-3 that expired last month (happens on the third annivers...

old 'n cranky — 5/8/2023 10:02:11 PM

FWIW they had an open s-3 that expired last month (happens on the third anniversary) so they needed a new one or they wouldn't be able to raise any funds.
This is an important excerpt:
"As of May 4, 2023, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was approximately $13,943,990, which was calculated based on 11,155,194 shares of outstanding common stock held by non-affiliates at a price of $1.25 per share, the closing price of our common stock on May 4, 2023. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding more than one-third of our “Public Float” (the market value of our common stock held by our non-affiliates) in any 12-months period so long as our Public Float remains below $75,000,000."

So this lofty sounding $150M shelf only really allows them access to less than $5M in financing over the next 12 months.

[Savant] Not with a ten foot pole...>> Nanoviricides (NYSE: NNVC) has filed for a $150M m...

Savant — 5/6/2023 12:46:48 PM

Not with a ten foot pole...>> Nanoviricides (NYSE: NNVC) has filed for a $150M mixed shelf securities offering.The company indicated it plans to use the proceeds for general corporate purposes. The offering can include common stock, preferred stock, debt securities, warrants, and units.

[Savant] more claims... NanoViricides looking at other uses for COVID drug candidate | S...

Savant — 4/25/2023 9:41:32 AM

more claims... NanoViricides looking at other uses for COVID drug candidate | Seeking Alpha

[Savant] What caused the pump....deal w/co in India to evaluate & license... However, Diw...

Savant — 4/10/2023 7:25:13 PM

What caused the pump....deal w/co in India to evaluate & license...
However, Diwan has his fingers in and gets a big cut, in that co. and all the others....arrgh

NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates | BioSpace

About Karveer Meditech Private Limited

Karveer Meditech Private Limited is a small and aspiring dynamic pharmaceutical company in India. It has developed and commercialized in local markets more than a dozen different generic and semi-branded pharmaceutical drugs as well as Ayurvedic medicines and vitaminized nutritional supplement protein powder products. It was co-founded by Dr. Anil Diwan, who serves as a Director and is a passive investor. Dr. Diwan is also co-founder of and President and Chairman of the Board of NanoViricides. Karveer Meditech is independently managed by its Managing Director in India.

[mattstat] The sham continues...

mattstat — 4/10/2023 5:01:49 PM

[old 'n cranky] I guess the news isn't blockbuster quality after all. Nobody seems to have notic...

old 'n cranky — 4/3/2023 4:20:34 PM

I guess the news isn't blockbuster quality after all. Nobody seems to have noticed.

[old 'n cranky] Did Diwan vote against the proposal to move the organization's domicile to Delaw...

old 'n cranky — 1/5/2023 9:49:04 AM

Did Diwan vote against the proposal to move the organization's domicile to Delaware? Wouldn't it have passed if he (and his controlled TheraCour property) voted for it?

[Savant] HTF...well...over promise, yes...under deliver..no....They've never delivered an...

Savant — 11/29/2022 4:41:22 PM

HTF...well...over promise, yes...under deliver..no....They've never delivered anything...other than PRs

[HardToFind] If history is any guide, any such bounce could be sold short as soon as it crest...

HardToFind — 11/29/2022 4:35:22 PM

If history is any guide, any such bounce could be sold short as soon as it crests...
Management's history is to over-promise and under-deliver. Given their history, unless there is a substantial change in management & governance, you can count on a drop following every pop in the stock price.

HTF...unless, wonder of all wonders...they actually produce something, or maybe even if they enter clinical trials.

Unless there's a change in management, I think we'd all be safe in shorting...

[Savant] HTF...unless, wonder of all wonders...they actually produce something, or mebbe ...

Savant — 11/3/2022 3:29:06 PM

HTF...unless, wonder of all wonders...they actually produce something, or mebbe even if they enter clinical trials..

[HardToFind] If history is any guide, any such bounce could be sold short as soon as it crest...

HardToFind — 11/3/2022 3:17:05 PM

If history is any guide, any such bounce could be sold short as soon as it crests...
Management's history is to over-promise and under-deliver. Given their history, unless there is a substantial change in management & governance, you can count on a drop following every pop in the stock price.

[Savant] "sounds promising".....It always does...

Savant — 10/14/2022 10:43:35 AM

[old 'n cranky] The press release that you provided to this board 5 years ago and that to this d...

old 'n cranky — 10/14/2022 10:39:07 AM

The press release that you provided to this board 5 years ago and that to this day remains as an introduction was promising too, wasn't it?

Using the word "promising" in a post about NNVC is shameful. Tell us why you continue to do so after having been shown to be wrong for so long.

[drkaz] Well - this sounds at least somewhat promising,... In the reported year, we bel...

drkaz — 10/14/2022 10:06:51 AM

Well - this sounds at least somewhat promising,...

In the reported year, we believe we have completed the IND-enabling pre-clinical drug development tasks pertaining to NV-CoV-2. Subsequently, we have received reports of all of the studies conducted externally. We have compiled the document called "Investigator's Brochure" pertaining to NV-CoV-2 that summarizes the developments and a potential clinical path for further discussion with a Clinical Research Organization (CRO).

We are now working on preparation of an Investigational New Drug (IND) application for filing with the US FDA. Our part of this application including primarily (i) Chemistry, Manufacture and Controls (CMC) information and (ii) Safety/Toxicology and Anti-viral Studies is substantially ready, and is being formatted into the appropriate IND formats. In addition, we are working on engaging a Clinical Research Organization (CRO) for completing the proposed clinical trials information section of the IND, and for executing the human clinical trials. Once this information is added to the IND application, we will be able to file the IND application.

Subsequent to the reported period, we have commissioned cGMP-compliant manufacture of the Drug Product formulations of NV-CoV-2 for use in the anticipated Phase 1 / 2 human Clinical trials.

We believe that NV-CoV-2 works by a novel mechanism of action, that of blocking the re-infection cycle of the viral disease. We believe that NV-CoV-2 not only binds to the virus, but fuses with the virus surface, uprooting the glycoproteins that are required for the virus to bind to the human cell (S protein, and its products S1 and S2 proteins), thereby rendering the virus incapable of infecting a cell. In contrast, antibodies are only capable of decorating the virus, generally incompletely.

In addition, as new variants have arisen a number of antibodies and antibody cocktails that have been developed and have received Emergency Use Authorizations (EUA) from the US FDA have had their EUA's revoked due to loss of effectiveness. The antibodies that continue to hold EUA are known to have significantly reduced activities against the newest Omicron variants that have begun to spread in the UK-Europe region, and are expected to reach the USA in a matter of months. We had clearly anticipated this problem of antibodies right at the beginning of the pandemic.

We developed NV-CoV-2 as a broad-spectrum, pan-coronavirus drug that is active not only against SARS-CoV-2, but also against other unrelated coronaviruses. As such, we believe it is highly unlikely that the generation of new variants of SARS-CoV-2 would allow the variant to escape NV-CoV-2. We believe this is exactly the kind of drug that is needed to combat the pandemic effectively and to be able to live with the virus, as a global society, as the SARS-CoV-2 virus is moving towards an endemic phase.

We were pleasantly surprised with the strong anti-viral effectiveness of orally administered NV-CoV-2 in our animal studies. We have therefore developed two oral formulations of this drug, (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. We believe that these formulations should provide highly effective treatment of SARS-CoV-2 variant infection in mild to moderate COVID-19 cases.

Additionally, we have developed (iii) NV-CoV-2 Solution for Injection, Infusion and Inhalation. We believe that infusion of NV-CoV-2 solution formulation in hospitalized cases is likely to be one of the best available treatments for COVID-19. We plan on studying injection rather than infusion, for its simplicity, and applicability to out-patient treatment (i.e. without hospitalization), which would be highly useful in the underdeveloped world populations. We believe that a combination of NV-CoV-2 given by infusion together with NV-CoV-2 given by direct lung inhalation would be a highly effective protocol for the treatment of severe lung disease caused by SARS-CoV-2. The inhalation, performed with a simple hand-held device, would deliver high concentrations of the drug directly at the sites of viral injury in lungs, enabling the strongest possible attack on the virus.

In addition to the strong effectiveness, the strong safety that we have observed in multiple animal models is suggestive that NV-CoV-2 can be used for treating children as well as adults, potentially spanning the age range potentially from infants to over 80 years old patients. If so, NV-CoV-2 would be the only oral drug with applicability to the entire human population. In contrast, remdesivir (Veklury(R), Gilead) is approved only for hospitalized patients, and Paxlovid(R) (Pfizer) was recently found to be not effective in patients less than 65 years old patients with no existing co-morbidities.

In addition to NV-CoV-2 itself as a drug to combat COVID-19, we are also developing another SARS-CoV-2 drug candidate, NV-CoV-2-R, which encapsulates remdesivir inside NV-CoV-2. While remdesivir substantially blocks the replication of the virus inside cells, NV-CoV-2 is designed to block the virus outside cells by entrapping it and thereby not allowing it to infect the cells in the first place. Thus, NV-CoV-2-R is designed to block both the intra-cellular life cycle of the virus and the extra-cellular life cycle of the virus. Blocking both lifecycles should enable complete control of the viral disease, promising a potential cure. Remdesivir, sponsored by Gilead, is a known antiviral drug that has received full US FDA approved for treatment of COVID-19 and has received EUA in many countries. We are developing NV-CoV-2-R on our own, independently of Gilead.

We intend to develop NV-CoV-2 through Phase1/2a clinical trials first, and anticipate clinical development of NV-CoV-2-R thereafter.

NV-CoV-2 and NV-CoV-2-R were found to be highly effective against a totally lethal coronavirus lung infection in an animal model study in rats based on multiple indicators. Treatment with the standard remdesivir formulation extended lifespan by only 2 days, while treatment with NV-CoV-2 and NV-CoV-2-R extended the lifespan by 8.5 and 10.5 days respectively; an extremely significant improvement attesting to a very strong effectiveness of our drug candidates.

NV-CoV-2 was found to be effective in cell cultures against infection by several unrelated coronaviruses, including SARS-CoV-2 pseudovirions (see the Company's press release dated October 11, 2021 for details). These studies have established that both NV-CoV-2 and NV-CoV-2-R are broad-spectrum, pan-coronavirus drugs and therefore would remain effective even as variants emerge.

In animal studies, our drugs NV-CoV-2 and NV-CoV-2-R have both exceeded the effectiveness of remdesivir, which is approved for treatment of severe hospitalized cases of COVID-19, and has shown substantial clinical benefit in clinical trials in moderate to severe COVID-19 patients. If the strong effectiveness of NV-CoV-2 and NV-CoV-2-R observed in animal studies is borne out in human clinical trials, then our drugs would be substantially more effective than existing therapies.

Previously, the Company has completed pre-clinical development of its lead drug candidate for the treatment of shingles rash, namely, NV-HHV-101. The Company intends to re-engage this program with filing an IND and performing clinical trials for NV-HHV-101 regulatory approvals after our COVID-19 program.

[old 'n cranky] sec.gov

old 'n cranky — 8/11/2022 4:52:52 PM

[old 'n cranky] Yes they have. No you haven't. If by follow up you mean accomplished anything, n...

old 'n cranky — 8/4/2022 1:49:10 PM

Yes they have.
No you haven't.
If by follow up you mean accomplished anything, no. They've definitely talked about it some more.

[Kirk ©] Haven't they said that about every virus way back to the H1N1 bird flus while th...

Kirk © — 8/4/2022 1:36:12 PM

Haven't they said that about every virus way back to the H1N1 bird flus while they keep failing to deliver their main one... or have I missed something since selling out in 2018?

Did they issue any follow-up to their "beginning to work no COVID" back in 2020?

[Savant] ONC A panacea.....but so far...no see 'em

Savant — 8/4/2022 10:54:16 AM

[old 'n cranky] Good call: accesswire.com Monkeycides!!!

old 'n cranky — 8/4/2022 8:28:32 AM

[Savant] NNVC up ystdy & tdy miracle cure for monkey pox????

Savant — 8/3/2022 2:26:43 PM

[old 'n cranky] Probably not very many, but I'll bet they're nice cars. And I'll bet they belong...

old 'n cranky — 6/8/2022 2:00:16 PM

Probably not very many, but I'll bet they're nice cars. And I'll bet they belong to people who get two paychecks every month.

[HardToFind] Just goes to show that bad management trumps good ideas every time. I need to re...

HardToFind — 6/8/2022 1:49:17 PM

Just goes to show that bad management trumps good ideas every time. I need to remind myself of that frequently.

[Kirk ©] Hard to believe how fast four years since dumping this dog flew by... Seems Pre...

Kirk © — 6/8/2022 10:01:17 AM

Hard to believe how fast four years since dumping this dog flew by...

Seems Press Releases remain their top product too.

I wonder how many cars are in the NNVC parking lot at 11AM each day?

[HardToFind] I'm guessing NNVC's MktCap is now below the cost of the facility in Shelton, CT....

HardToFind — 6/8/2022 2:15:42 AM

I'm guessing NNVC's MktCap is now below the cost of the facility in Shelton, CT.

May 16, 2022: "NanoViricides expects filing a clinical trial application for COVID-19 to occur relatively soon, although the timelines are outside the company's control."

Hmmm...filing a clinical trial application...timelines are outside the company's control.

The story never changes...not our fault...out of our control...blame the cabal of naked shortsellers. The company specializes in perfecting their victim mentality and proving their inability to control (or even influence) the future of their drug development programs.

Total losers.

[Thomas M.] Engineered bat virus stirs debate over risky research Lab-made coronavirus re...

Thomas M. — 9/22/2021 1:27:20 AM

Engineered bat virus stirs debate over risky research

Lab-made coronavirus related to SARS can infect human cells.

nature.com

Wow, prescient post!

Tom

[HardToFind] He'll have to get into a long line...he won't be the first.

HardToFind — 5/16/2021 2:22:12 AM

[Savant] Would El say the same thing? "It's a hustle"?

Savant — 5/15/2021 1:06:08 PM

[HardToFind] NNVC is the Dogecoin of biotech!!! Let's get Elon to talk about it on SNL...

HardToFind — 5/14/2021 11:54:06 PM

[mattstat] You live?

mattstat — 1/29/2021 5:45:41 PM

[donpat] Medicago has been privately held since 2013. https://www.medicago.com/en/about...

donpat — 1/26/2021 12:49:05 PM

Medicago has been privately held since 2013.

https://www.medicago.com/en/about-us/

[donpat] Medicago About UsTechnologiesDiscoveryPipelineCOVID-19Media RoomPublicationsCon...

donpat — 1/26/2021 12:38:41 PM

Medicago

About Us Technologies Discovery Pipeline COVID-19 Media Room Publications Contact CAREERS FR

Leading the way in plant-based vaccine technology

P L A YV I D E O

COVID-19Development Programs

Plant-based Vaccine Technology
Latest news

December 4, 2020
Takashi Nagao appointed President and Chief Executive Officer of Medicago
Read more

November 12, 2020
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
Read more

November 10, 2020
Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate
Read more

HOW WE'RE CHANGING THE GAME

Medicago's technologies represent a disruptive approach to vaccines, therapeutic proteins, and disease response.

Plant-Based Manufacturing
This platform brings many advantages, including faster lead time, scalability and versatility.

Learn more

Virus-Like Particles (VLPs)
VLPs mimic the native structure of a virus but do not contain the genetic material.

Learn more

Discovery Platforms
Our unique screening platform accelerates the discovery of new recombinant proteins.

Learn more

WHAT WE'RE WORKING ON
Medicago's proven discovery and development platform is scalable and versatile, allowing us to build a robust and limitless product pipeline.

Coronavirus

Influenza

Rotavirus

https://www.medicago.com/en/

[old 'n cranky] Yay me! :o)

old 'n cranky — 9/19/2020 5:33:42 PM

[HardToFind] This won't happen: "Forced into success by a lawsuit...that has to be a rare occ...

HardToFind — 9/19/2020 4:54:42 PM

This won't happen: "Forced into success by a lawsuit...that has to be a rare occurrence."Diwan can't be forced or cajoled or paid into an NNVC success. I don't think it's even part of his plan.

You're right on multiple counts. In all likelihood...

There will be no lawsuit.
There will be no success of the company.

[old 'n cranky] What lawsuit? No lawsuit is likely. Two whole months ago a couple of ambulance c...

old 'n cranky — 9/17/2020 7:12:45 AM

What lawsuit? No lawsuit is likely.
Two whole months ago a couple of ambulance chasers tried to get a fire started and we haven't heard from them since. Little wonder, they didn't make much of a case to bring a suit.
One said ...
“We’re focused on investors’ losses and whether NanoViricides has accurately represented the work it is doing toward a potential COVID-19 and other treatments,” said Reed Kathrein, the Hagens Berman partner leading the investigation. “We welcome any and all leads that could assist us in protecting investors.”

The other said ......
"The securities investigation concerns whether NanoViricides provided false or misleading information to investors about its activities related to drug development, including a potential treatment for COVID-19."

Do you really think that these folks will be able to show that NanoViricides hasn't accurately represented the work it is doing toward a potential COVID-19 and other treatments, providing false or misleading information to investors about its activities related to drug development in the process?

Even though those things might very well be true they need to be SHOWN and most of these guys don't like to do the necessary work. Besides, if investors don't do everything they can to avoid being misled through their own due diligence they wouldn't seem to have earned the protection of the Court.

It's interesting that the Hagens Berman release says "Relevant Period: Before July 14, 2020".
You know that's not a period, right? They're going to need to determine a claim period. When would you think the appropriate starting date for that might be? Some time in 2005 or whenever the original license was "granted"?

This won't happen: "Forced into success by a lawsuit...that has to be a rare occurrence."
Diwan can't be forced or cajoled or paid into an NNVC success. I don't think it's even part of his plan.

[HardToFind] Can one sink a ship that's already on it's way to the bottom of the ocean?

HardToFind — 9/17/2020 1:28:53 AM

[HardToFind] This lawsuit might even light a fire underneath management to get a drug into hu...

HardToFind — 9/16/2020 9:48:38 PM

This lawsuit might even light a fire underneath management to get a drug into human trials...something they have never done before.

Forced into success by a lawsuit...that has to be a rare occurrence. Mind you, the NNVC shareholders will still retain the right to finance Diwan's business aspirations without any obligation to share in the proceeds.

[old 'n cranky] NNVC wouldn't be the only defendant. Thank goodness for the plaintiffs: "The Com...

old 'n cranky — 9/16/2020 8:51:13 PM

NNVC wouldn't be the only defendant. Thank goodness for the plaintiffs:
"The Company also maintains a limited amount of Directors and Officers Liability insurance coverage to protect all of its directors and executive officers taken together. There can be no assurance that this D&O coverage will be sufficient to cover the costs of the events that may lead to its invocation, in which case, there could be a substantial impact on the Company’s ability to continue operations, should such an unforeseen event occur."

Diwan would surely be a defendant, bringing TheraCour into the party. And others.

Defendants are easy to come by, but it's not clear that a case can be made.

[HardToFind] I think the class-action attorneys have another problem: NNVC has minimal money ...

HardToFind — 9/16/2020 7:16:31 PM

I think the class-action attorneys have another problem: NNVC has minimal money and/or assets. It could be a long walk from the courthouse to the bank. Maybe they could get some of those invaluable NNVC shares?

[HardToFind] They're fishing for a lead plaintiff and taking longer to catch one than it shou...

HardToFind — 9/16/2020 3:59:04 PM

They're fishing for a lead plaintiff and taking longer to catch one than it should take.

If only they would open up their lawsuit to corporate behavior over the last 15 years instead of just 9 months, I could be quite helpful. (Hell...I think I have an audio of their lawyer lying to me during an annual shareholder meeting Q&A, certainly making a blatantly deceptive statement.)

But I used the last speculative Covid-19 bounce to sell out at $12, so I can't really claim I have been harmed by their recent drug campaign...although whoever I sold my shares to was certainly adversely affected. (Sorry about that...)